Parabilis Medicines, Inc. Research and Development Expense
Parabilis Medicines, Inc. (PBLS) reported Research and Development Expense of $39.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Parabilis Medicines, Inc. research and development expense for the quarter ending 2026-06-30 was $39.38M, a 30.71% increase year-over-year.
- Parabilis Medicines, Inc. research and development expense for the quarter ending 2025-06-30 was $30.13M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $39.38M 10-Q · filed 2026-08-13 | $77.13M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $30.13M 10-Q · filed 2026-08-13 | $64.03M 10-Q · filed 2026-08-13 |